Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2021

01-12-2021 | Breast Cancer | Correction

Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study

Authors: Antonella Ciabattoni, Fabiana Gregucci, Gerd Fastner, Silvio Cavuto, Antonio Spera, Stefano Drago, Ingrid Ziegler, Maria Alessandra Mirri, Rita Consorti, Felix Sedlmayer

Published in: Breast Cancer Research | Issue 1/2021

Login to get access

Excerpt

Correction to: Breast Cancer Res 23, 46 (2021) …
Literature
1.
Metadata
Title
Correction to: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study
Authors
Antonella Ciabattoni
Fabiana Gregucci
Gerd Fastner
Silvio Cavuto
Antonio Spera
Stefano Drago
Ingrid Ziegler
Maria Alessandra Mirri
Rita Consorti
Felix Sedlmayer
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-021-01432-9

Other articles of this Issue 1/2021

Breast Cancer Research 1/2021 Go to the issue

Research article

Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells

Research article

Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study

Research article

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study

Review

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Research article

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Research article

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits